Characteristics of 22 patients with LPHD
. | Relapsed, n = 10 . | Untreated, n = 12 . |
|---|---|---|
| Male-female ratio | 8:2 | 8:4 |
| Age, median (range), y | 44 (29-61) | 45 (18-63) |
| Stage/relapse stage | ||
| I | 3 | 4 |
| II | 4 | 3 |
| III | 3 | 5 |
| B symptoms | 0 | 2 |
| No. of lymph node regions involved | ||
| 1-2 | 5 | 7 |
| 3-4 | 3 | 4 |
| More than 4 | 2 | 1 |
| Relapse history | ||
| 1st relapse | 6 | NA |
| 2nd relapse | 3 | NA |
| 4th relapse | 1 | NA |
| Prior treatment | ||
| Radiotherapy | NA | |
| IF | 2 | NA |
| Regional* | 3 | NA |
| STLI | 2 | NA |
| Chemotherapy | ||
| MOPP | 3 | NA |
| ABVD | 2 | NA |
| MOPP/ABVD | 2 | NA |
| CHOP | 1 | NA |
. | Relapsed, n = 10 . | Untreated, n = 12 . |
|---|---|---|
| Male-female ratio | 8:2 | 8:4 |
| Age, median (range), y | 44 (29-61) | 45 (18-63) |
| Stage/relapse stage | ||
| I | 3 | 4 |
| II | 4 | 3 |
| III | 3 | 5 |
| B symptoms | 0 | 2 |
| No. of lymph node regions involved | ||
| 1-2 | 5 | 7 |
| 3-4 | 3 | 4 |
| More than 4 | 2 | 1 |
| Relapse history | ||
| 1st relapse | 6 | NA |
| 2nd relapse | 3 | NA |
| 4th relapse | 1 | NA |
| Prior treatment | ||
| Radiotherapy | NA | |
| IF | 2 | NA |
| Regional* | 3 | NA |
| STLI | 2 | NA |
| Chemotherapy | ||
| MOPP | 3 | NA |
| ABVD | 2 | NA |
| MOPP/ABVD | 2 | NA |
| CHOP | 1 | NA |
IF indicates involved field; STLI, subtotal lymphoid irradiation; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; and NA, not applicable.
Mantle (1 pt), Mini-mantle (1 pt), Inverted-Y (1 pt).